Workflow
凯莱英(002821):剔除大订单实现稳健增长,盈利能力回到较高水平
002821Asymchem(002821) 平安证券·2025-03-31 07:46

Investment Rating - The report maintains a "Strong Buy" rating for the company, expecting the stock to outperform the market by over 20% within the next six months [11]. Core Views - The company achieved a revenue of 5.805 billion yuan in 2024, a year-over-year decrease of 25.82%, and a net profit of 949 million yuan, down 58.17% year-over-year. The company plans to distribute a dividend of 11 yuan per 10 shares (including tax) [3]. - The company’s core small molecule chemistry business generated revenue of 4.571 billion yuan in 2024, with a year-over-year growth of 8.85% when excluding large orders. The gross margin for this segment was 47.95% [6]. - The company has signed new orders that are expected to grow by approximately 20% year-over-year, with a total order backlog of 1.052 billion USD, which is expected to significantly cover revenue for 2025 [6][7]. - The company is expanding its global footprint with the opening of the Sandwich base in the UK, which is expected to enhance its ability to meet overseas customer needs and mitigate geopolitical risks [7]. Summary by Sections Financial Performance - In 2024, the company reported a total revenue of 5.805 billion yuan, with a net profit of 949 million yuan. The revenue is projected to increase to 6.700 billion yuan in 2025, with a net profit forecast of 1.126 billion yuan [5][8]. - The gross margin is expected to improve from 42.4% in 2024 to 43.7% in 2025, while the net margin is projected to rise from 16.3% to 16.8% [9]. Business Segments - The small molecule chemistry segment is expected to continue its growth trajectory, with a projected revenue increase to 6.700 billion yuan in 2025 [5][6]. - Emerging businesses, particularly in the chemical macromolecule sector, are anticipated to accelerate, with 13 new projects expected by 2025 [7]. Market Position and Strategy - The company is strategically positioning itself to capture opportunities in the peptide and small nucleic acid markets, enhancing its competitive edge [7]. - The establishment of overseas bases is aimed at attracting clients who prefer not to outsource offshore, thereby maintaining a cost advantage over local competitors [7].